Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial

被引:93
|
作者
Swartz, MS [1 ]
Perkins, DO [1 ]
Stroup, TS [1 ]
McEvoy, JP [1 ]
Nieri, JM [1 ]
Haak, DC [1 ]
机构
[1] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27710 USA
关键词
outcome measures; psychopathology assessment; functional assessment; schizophrenia treatment;
D O I
10.1093/oxfordjournals.schbul.a006989
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Schizophrenia is a symptomatically heterogeneous disorder characterized by the presence of positive and negative symptoms, and variable impairment in community functioning. Given the diversity of symptom presentations and functioning associated with schizophrenia, one of the key challenges facing the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial was the selection of efficient assessment measures appropriate to a community-based effectiveness trial. This article describes the rationale for the measurement approach adopted for the trial, provides a brief overview of the selected measures, and describes the process of training assessment raters for a large and geographically dispersed study group.
引用
收藏
页码:33 / 43
页数:11
相关论文
共 50 条
  • [1] Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: Primary efficacy and safety outcomes of the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial
    Lieberman, JA
    Stroup, TS
    McEvoy, JP
    Swartz, MS
    Rosenheck, RA
    Perkins, DO
    Keefe, RS
    Davis, SM
    Davis, CE
    Lebowitz, B
    Hsiao, J
    Severe, J
    [J]. NEUROPSYCHOPHARMACOLOGY, 2005, 30 : S32 - S32
  • [2] The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: Clinical comparison of subgroups with and without the metabolic syndrome
    Meyer, JM
    Nasrallah, HA
    McEvoy, JP
    Goff, DC
    Davis, SM
    Chakos, M
    Patel, JK
    Keefe, RSE
    Stroup, TS
    Lieberman, JA
    [J]. SCHIZOPHRENIA RESEARCH, 2005, 80 (01) : 9 - 18
  • [3] Commentary on the clinical antipsychotic trials of intervention effectiveness (CATIE)
    Kane, John M.
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2006, 67 (05) : 831 - 832
  • [4] Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial
    Schneider, LS
    Ismail, MS
    Dagerman, K
    Davis, S
    Olin, J
    McManus, D
    Pfeiffer, E
    Ryan, JM
    Sultzer, DL
    Tariot, PN
    [J]. SCHIZOPHRENIA BULLETIN, 2003, 29 (01) : 57 - 72
  • [5] Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study
    Volavka, Jan
    Czobor, Pal
    Citrome, Leslie
    Van Dorn, Richard A.
    [J]. CNS SPECTRUMS, 2014, 19 (05) : 374 - 381
  • [6] Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: Development, methodology, and rationale
    Keefe, RSE
    Mohs, RC
    Bilder, RM
    Harvey, PD
    Green, MF
    Meltzer, HY
    Gold, JM
    Sano, M
    [J]. SCHIZOPHRENIA BULLETIN, 2003, 29 (01) : 45 - 55
  • [7] Evaluation of "subject advocate" procedures in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia study
    Stroup, TS
    Appelbaum, PS
    [J]. SCHIZOPHRENIA BULLETIN, 2006, 32 (01) : 147 - 152
  • [8] Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians?
    Citrome, L.
    Stroup, T. Scott
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2006, 60 (08) : 933 - 940
  • [9] Evaluating the evidence: Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and beyond
    Nasrallah, Henry A.
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2007, 68 : 3 - 4
  • [10] Introduction: An overview of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study
    McEvoy, Joseph P.
    [J]. CNS SPECTRUMS, 2006, 11 (07) : 4 - 8